{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:28:51Z","timestamp":1789475331439,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The current widespread use of sodium-glucose co-transporter 2 (SGLT2) inhibitors has triggered an increase in reported cases of euglycemic diabetic ketoacidosis (EDKA), often characterized by a protracted metabolic acidosis that is resistant to conventional DKA treatment. We report a case of empagliflozin-induced EDKA with severe metabolic acidosis intractable to aggressive fluid resuscitation and boluses of bicarbonate infusion. Following the introduction of high-calorie glucose infusion coupled with tight glycemic control, the recalcitrant acidosis was successfully corrected. This is the first case report that adopts the above approach, representing a paradigm shift in the management of SGLT2 inhibitor-induced EDKA.<\/jats:p>","DOI":"10.3389\/fendo.2022.867647","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T09:19:25Z","timestamp":1654075165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Siti Sanaa","family":"Wan Azman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norlela","family":"Sukor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Yusuf","family":"Abu Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilham","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Azmi","family":"Kamaruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dom.13650","article-title":"A Review of the Mechanism of Action, Metabolic Profile and Haemodynamic Effects of Sodium-Glucose Co-Transporter-2 Inhibitors","author":"Brown","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients With Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1574886314666190206164647","article-title":"Safety of SGLT2 Inhibitors in Patients With Diabetes Mellitus","volume":"14","author":"Singh","year":"2019","journal-title":"Curr Drug Saf"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251","article-title":"Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic Diabetic Ketoacidosis Induced by SGLT2 Inhibitors: Possible Mechanism and Contributing Factors","volume":"7","author":"Ogawa","year":"2015","journal-title":"J Diabetes Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 Inhibitors May Predispose to Ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.05.011","article-title":"SGLT-2 Inhibition and Glucagon: Cause for Alarm","volume":"26","author":"Kibbey","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic Response to Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetic Patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in Endocrinology: SGLT2 Inhibitors: Clinical Benefits by Restoration of Normal Diurnal Metabolism","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837664","article-title":"Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters","volume":"13","author":"Armour","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1881","article-title":"SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 Inhibitors and Diabetic Ketoacidosis: Data From the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"B16","unstructured":"Drug Safety AnnouncementFDA Warns That SGLT2 Inhibitors for Diabetes may Result in a Serious Condition of Too Much Acid in the Blood"},{"key":"B17","unstructured":"EMA Confirms Recommendations to Minimize Ketoacidosis Risk With SGLT2 Inhibitors for Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A Method for Estimating the Probability of Adverse Drug Reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report and Review of the Literature","volume":"12","author":"Diaz-Ramos","year":"2019","journal-title":"Int J Emerg Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic Ketoacidosis: A Review","volume":"13","author":"Modi","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged Acidosis Is a Feature of SGLT2i-Induced Euglycaemic Diabetic Ketoacidosis","volume":"2019","author":"Rafey","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.867647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T09:19:29Z","timestamp":1654075169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.867647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":21,"alternative-id":["10.3389\/fendo.2022.867647"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.867647","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"article-number":"867647"}}